#Genome Editing Market Size

[healthcare-updates-with-sns]

Genome Editing Market: Market Trends and Market Analysis 2024-2032

The Genome Editing Market was valued at USD 6.46 Billion in 2023 and is projected to reach USD 25.99 Billion by 2031, growing at a compound annual growth rate (CAGR) of 18.9% during the forecast period from 2024 to 2031. This remarkable growth is attributed to the increasing demand for precise and effective gene therapies, rapid advancements in CRISPR technology, and a surge in research funding related to genomics and biotechnology.

Market Overview

Genome editing, also known as gene editing, is a powerful tool that allows scientists to alter DNA within organisms. This technique is being widely adopted across healthcare, agriculture, and research sectors to treat genetic disorders, enhance crop traits, and study gene functions. The growth of the genome editing market is being accelerated by rising investments in R&D, increasing prevalence of genetic diseases, and expanding applications in drug development and regenerative medicine.

Get Free Sample Report @ https://www.snsinsider.com/sample-request/3944

Regional Analysis

North America currently dominates the genome editing market due to its well-established healthcare infrastructure, strong presence of key industry players, and robust investment in genetic research. The region's leadership in adopting advanced technologies and favorable regulatory policies supports ongoing innovation.

Europe follows closely, benefiting from substantial government initiatives and funding for genomic research. Meanwhile, the Asia-Pacific region is emerging as a lucrative market, driven by increasing healthcare expenditure, a growing biotechnology sector, and supportive government policies in countries like China, Japan, and India.

Market Segmentation

The genome editing market is segmented based on:

Technology: CRISPR, TALEN, ZFN, Antisense, and Others

Application: Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, and Others

End-Use: Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research Organizations (CROs)

CRISPR continues to lead the technology segment due to its simplicity, efficiency, and cost-effectiveness compared to other genome editing tools.

Key Players

Merck KGaA - CRISPR-Cas9 Gene Editing Platform

Cibus Inc. - Rapid Trait Development System (RTDS)

Recombinetics - Gene Editing for Animal Health and Agricultural Biotechnology

Sangamo Therapeutics - Zinc Finger Nucleases (ZFNs)

Editas Medicine - EDIT-101 (CRISPR-based Gene Therapy)

Precision BioSciences - Arcus Gene Editing Platform

CRISPR Therapeutics - CTX001 (CRISPR-based Therapy for Genetic Disorders)

Intellia Therapeutics, Inc. - NTLA-2001 (CRISPR-based Therapeutic)

Caribou Biosciences, Inc. - CRISPR-Cas12a and CRISPR-Cas9 Technologies

Cellectis S.A. - TALEN Gene Editing System

AstraZeneca - CRISPR Gene Editing Research Initiatives

Takara Bio Inc. - Gibson Assembly and CRISPR/Cas9 Systems

Horizon Discovery Ltd. (Revvity, Inc.) - GENESIS Gene Editing Services

Danaher Corporation - EditR (Gene Editing Platform)

Transposagen Biopharmaceuticals, Inc. - Transposon-based Gene Editing Technologies

Genscript Biotech Corp - CRISPR Gene Editing Kits and Services

New England Biolabs - CRISPR Enzymes and Tools

OriGene Technologies, Inc. - CRISPR/Cas9 Gene Editing Tools

Bluebird Bio, Inc. - LentiGlobin (Gene Therapy for Genetic Disorders)

Lonza - Lonza’s Genome Editing Services

Thermo Fisher Scientific, Inc. - GeneArt CRISPR Nuclease Kits and Services

Key Points:

Market projected to grow at a CAGR of 18.9% from 2024 to 2031

CRISPR remains the dominant technology with broad research and therapeutic use

Rising prevalence of genetic disorders fueling demand for genome editing tools

North America holds the largest market share, followed by Europe and Asia-Pacific

Increased public and private funding supports R&D in genome editing

Expanding application across agriculture, medicine, and biotech research

Future Scope

The future of the genome editing market looks promising, with significant growth potential in personalized medicine, gene therapy, and synthetic biology. Innovations in delivery systems, ethical regulation development, and expanding clinical applications are expected to shape the next phase of market evolution. Additionally, collaborations between biotech firms, academic institutions, and regulatory bodies will accelerate the transition of genome editing from the lab to mainstream healthcare.

Conclusion

With its transformative impact on healthcare and agriculture, the genome editing market is poised for substantial growth over the coming years. Technological innovations, supportive regulatory frameworks, and increasing global investment in genomics are set to propel the industry into a new era of precision science and personalized treatment.

Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Other Related Reports:

Cell Viability Assay Market

Medical Power Supply Market

Post Traumatic Stress Disorder Treatment Market

MRI Guided Neurosurgical Ablation Market

[introvertedwolf]

oh my GOD i have so many thoughts on this shit.

first of all, HORRENDOUS marketing. Colossal Biosciences is doing INSANELY scummy shit, and they have tried to "bring back" creatures like woolly mammoths and dodos with no real success. i'd bet my bottom dollar they're trying to use this language for this project as a "proof of concept" to sell to investors, because THEY DID NOT DO SHIT.

they edited, by their own admission, 14 total genes, making 20 changes between them, using CRISPR technology (which is entirely it's own mess of a situation and probably doesnt give us the degree of control its usually sold as, but thats an entirely different can of worms)

but i need to make it clear. MOST OF THOSE CHANGES. WERE TO COLOR. other changes were to ear size, body size, and fur texture.

THEY MADE TIMBER WOLVES. THAT ARE WHITE. AND CALLING THEM DIRE WOLVES.

and if that wasn't bad enough, Dire Wolf were Not related to wolves. they're not in the same genus. dire wolves are most closely related to african jackals and african painted dogs than anything else currently alive. theyre more closely related to my niche canine blorbo The Dhole than any extant wolf species, particularly north american ones.

and lets be clear, even with jackals being the most related currently alive species, jackals are still more closely related to timber wolves than either one is to the dire wolf.

there are LITERALLY MILLIONS of genes worth of difference between grey wolves and jackals, and millions MORE between jackal and dire wolf. and they edited FOURTEEN. and CALLED IT A DIRE WOLF.

dire wolf were only Called that because they had similar skeletal shapes and pack hunting behavior, but currently we think they'd look more like a jackal or coyote than anything else. and reconstructing COLOR? spending MOST OF YOUR EDITS ON COLOR? this is not at all what a direwolf would look like, even remotely, and it CERTAINLY wont tell us anything about how they BEHAVED.

they make claims about how they want to release these animals into the wild (to their "rightful place" as their website says), but the ecological niche that dire wolf filled no longer exists. dire wolf are a species of megafauna, who specialized in hunting other megafauna. the only living species of megafauna is moose, and modern timber wolves, bear and humans are known for hunting those just fine. if you released a dire wolf into the north american wilds, it would compete with endangered timber wolves for resources.

its one thing to save a species from wild extinction that experienced it recently, where its niche was not otherwise filled, but wolves DID fill that niche. introducing a dire wolf at this point would have the same issues as introducing an invasive species. this was not a species that RECENTLY went extinct in the wild. there is no longer space to support an animal like a dire wolf in the wild.

they say they're "committed to transparency," but they refused to release the 2 complete dire wolf genomes they used to splice into the pups DNA. when it comes to welfare, they've refused to explain what species of surrogate they used (most speculate it was a domestic dog) or what care conditions for those are/were.

this is a flagrant marketing ploy, its total BS.

and not for nothing, the Colossal Biosciences website uses AI generated images.

this company is so frustratingly misleading. They did not bring back the direwolf (Aenocyon dirus). They modified a modern grey wolf (Canis lupus) into having some direwolf morphology. There has been no de-extinction. This is pure hype slop. As a friend said "these are dire wolves the same way La Croix is a fruit".

[industrynewsupdates]

Nucleic Acid Isolation and Purification Market: Challenges and Opportunities

According to a recent report by Grand View Research, Inc., the global nucleic acid isolation and purification market is projected to reach a value of USD 9.77 billion by the year 2030. This market is expected to grow at a robust compound annual growth rate (CAGR) of 9.61% from 2025 to 2030. The anticipated growth of this market is largely driven by several critical factors, including the rising global incidence of cancer and chronic diseases, as well as the increasing availability of public and private funding for research in biotechnology and life sciences. Governments and private organizations around the world are continuously investing in biomedical research to enhance diagnostics, therapeutic development, and precision healthcare—all of which rely heavily on effective nucleic acid isolation and purification techniques.

In addition to disease prevalence and funding support, significant progress in automation and advanced technology is accelerating the market’s expansion. Automation has drastically improved the speed, reproducibility, and accuracy of nucleic acid extraction processes, making it easier to handle high-throughput workflows in both research and clinical laboratories. The growing global demand for genetically modified organisms (GMOs) and crops—driven by the need for improved agricultural productivity and food security—is also contributing to the rising adoption of nucleic acid purification tools. A notable example is the advancement by HiMedia Laboratories in December 2023, where the company highlighted the effectiveness of magnetic bead-based extraction systems. These systems offer superior efficiency and scalability in nucleic acid isolation and have found applications across multiple end-use industries, including pharmaceuticals, agriculture, and diagnostics.

A major area benefiting from nucleic acid isolation and purification technologies is precision medicine. This field involves tailoring medical treatment to individual genetic profiles, and it continues to expand rapidly, particularly in addressing complex conditions such as cancer, diabetes, rheumatoid arthritis, neurological disorders, and autoimmune diseases. Precision medicine has introduced new approaches to gene manipulation, enabling the development of therapies that target specific genetic abnormalities. For example, various companies are investing in delivery platforms for nucleic acids—such as small interfering RNAs (siRNAs)—which are designed to modulate gene expression and correct mutations linked to numerous health conditions. These platforms aim to treat diseases that were previously considered untreatable by conventional therapies. As researchers strive to develop more effective and personalized treatments, the importance of nucleic acid isolation and purification technologies becomes even more critical in enabling these breakthroughs.

Furthermore, research and development (R&D) efforts in human genomics, primarily led by pharmaceutical and biotechnology companies, have significantly advanced the diagnosis and treatment of diseases. Nucleic acid isolation and purification kits and instruments are indispensable in several areas of biomedical research, particularly in the development of new drugs, the identification of therapeutic targets, and gene-editing applications. These technologies serve as foundational tools in genome sequencing, cloning, and functional genomics studies.

Curious about the Nucleic Acid Isolation And Purification Market? Download your FREE sample copy now and get a sneak peek into the latest insights and trends. 

Here are some commonly asked questions related to the Nucleic Acid Isolation And Purification Market, along with answers that provide essential insights.

1. How big is the nucleic acid isolation and purification market?

The global nucleic acid isolation and purification market size was estimated at USD 5.75 billion in 2024 and is expected to reach USD 6.17 billion in 2025.

2. What is the nucleic acid isolation and purification market growth?

The global nucleic acid isolation and purification market is expected to witness a compound annual growth rate of 9.61% from 2025 to 2030 to reach USD 9.77 billion by 2030.

3. Which product accounted for the largest nucleic acid isolation and purification market share?

Kits and reagents accounted for the largest share in 2024 due to the wide availability of robust kits for isolation of DNA or RNA from the given sample contributed to the dominance of this segmen

4. Who are the key companies/players in the nucleic acid isolation and purification market?

Some key players operating in the nucleic acid isolation and purification market include Thermo Fisher Scientific, Inc., QIAGEN, Merck KGaA, Illumina, Inc., Danaher, F. Hoffmann-La Roche Ltd, Agilent Technologies, Bio-Rad Laboratories, Inc., Takara Bio Inc., Promega Corporation

5. What are the factors driving the nucleic acid isolation and purification market?

Expanding pipeline for RNA therapeutics, plummeting sequencing cost, and growing popularity of nucleic acid-based diagnostics are some key driving factors of the nucleic acid isolation & purification market.

Order a free sample PDF of the Nucleic Acid Isolation And Purification Market Intelligence Study, published by Grand View Research.

[simranmodi18]

Genomics Market Report: Industry Overview, Trends, and Forecast (2025-2034)

Genomics Market Overview

The genomics market has emerged as a cornerstone in the realm of modern healthcare and biomedical research, offering critical insights into the genetic basis of disease, patient predispositions, and tailored treatment strategies. Genomics enables a deeper understanding of gene functions, interactions, and variations, driving innovations in personalized medicine, drug discovery, and diagnostics. With rapid advancements in genetic research and technology, the global genomics market is playing a vital role in revolutionizing healthcare delivery and precision medicine.

Genomics Market Size and Share

In 2024, the global genomics market size was valued at USD 45.77 billion, underpinned by the expansion of genomic technologies, integration of artificial intelligence, and increasing healthcare investments. The market is projected to witness a robust compound annual growth rate (CAGR) of 10.20% during the forecast period from 2025 to 2034. By 2034, the genomics market is expected to reach USD 120.89 billion. This remarkable growth is driven by rising demand for personalized treatment, the surge in cancer cases requiring comprehensive genomic profiling, and the widespread adoption of genomics in pharmaceutical R&D.

Genomics Market Trends

One of the prominent trends in the genomics market is the growing application of Next-Generation Sequencing (NGS) in clinical diagnostics and precision medicine. NGS allows for rapid and comprehensive DNA/RNA sequencing, significantly reducing the time and cost of genomic analysis. Its adoption has been instrumental in early disease detection, especially in oncology and rare genetic disorders, providing actionable insights for tailored therapies.

Another trend shaping the market is the rise of consumer genomics. Services like ancestry and health risk analysis have gained immense popularity, enabling individuals to gain personal insights into their genetic heritage and predispositions. The availability of affordable direct-to-consumer tests from companies like 23andMe and AncestryDNA has broadened market accessibility and awareness.

Gene editing technologies such as CRISPR-Cas9 are also revolutionizing the genomics industry. These tools enable precise editing of genes, offering potential cures for inherited diseases and novel therapeutic avenues. Ongoing research and clinical trials involving CRISPR-based treatments underscore its transformative impact on modern medicine.

Furthermore, integration of AI and machine learning in genomics is enhancing data interpretation and predictive modeling. These technologies facilitate the analysis of massive genomic datasets, improve diagnostic accuracy, and support the identification of novel drug targets. This convergence is fueling the development of next-generation genomic platforms with higher efficiency and scalability.

Genomics Market Analysis

The demand for comprehensive genomic profiling (CGP) in oncology is a major market driver, aiding in personalized treatment strategies. CGP enables identification of genetic mutations responsible for cancer progression, improving patient outcomes.

The growing investments by governments and private players in genomic research have accelerated innovations. Initiatives like the Human Genome Project and national genome sequencing programs have laid the foundation for large-scale genetic databases.

Partnerships and collaborations among key industry players are fostering product innovation and expanding market reach. These alliances aim to combine expertise in sequencing technologies, software development, and clinical diagnostics.

Regulatory frameworks and ethical concerns, particularly around data privacy and gene editing, continue to pose challenges. Establishing standardized guidelines is critical to ensure patient safety and responsible use of genomic technologies.

Genomics Scope of the Report

This report provides comprehensive insights into the global genomics market, covering historical trends and future projections. It includes an in-depth segmentation by offering, technology, application, end user, and region. The analysis highlights key growth drivers, market constraints, and emerging opportunities within each segment, offering a complete view of the industry landscape from 2025 to 2034.

Be Informed. Be Prepared. Global Genomics Market Trends Await! Analyse key developments and prospects. Free access – download now!

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment

Breakup by Offering

Products

Instruments/Systems

Software

Consumables & Reagents

Services

NGS-based Services

Core Genomics Services

Biomarker Translation Services

Computational Services

Others

Breakup by Technology

Sequencing

PCR (Polymerase Chain Reaction)

Flow Cytometry

Microarrays

Others

Breakup by Application

Drug Discovery and Development

Functional Genomics

Biomarker Discovery

Pathway Analysis

Epigenomics

Diagnostics

Breakup by End User

Pharmaceutical and Biotechnology Companies

Hospitals and Clinics

Diagnostic Laboratories

Academic and Research Institutes

Others

Genomics Regional Insights

North America remains the leading region in the genomics market, driven by advanced healthcare infrastructure, robust funding in genomic research, and the presence of key market players. The U.S. dominates the regional landscape due to the high adoption of genomic technologies in clinical and research settings. Government initiatives like the Precision Medicine Initiative have further bolstered market growth.

Asia Pacific is emerging as a fast-growing region, propelled by increasing investments in healthcare and biotechnology. Countries like China, Japan, and India are embracing genomics for disease prevention, agriculture, and personalized medicine. Growing awareness, rising healthcare expenditure, and a strong base of clinical trials support the market expansion in this region.

Genomics Market Growth

Several factors are driving the growth of the genomics market. These include the rising prevalence of chronic diseases, growing interest in preventive healthcare, and increasing adoption of precision medicine. Technological advancements in sequencing, bioinformatics, and gene editing tools are expanding the scope of genomics. Moreover, the growth of telemedicine and digital health platforms is facilitating genomic data sharing and remote consultations, opening new avenues for market expansion.

Recent Developments & Challenges

Illumina launched NovaSeq X Series: In 2024, Illumina introduced its most powerful sequencer, the NovaSeq X, capable of delivering faster and more affordable sequencing. This innovation aims to democratize access to genomic data globally.

FDA Approved CRISPR-based Therapy: The U.S. FDA approved a landmark CRISPR-Cas9 gene-editing therapy for sickle cell disease, marking a significant milestone in gene therapy regulation and commercialization.

Collaboration between Thermo Fisher and Moderna: Thermo Fisher Scientific expanded its strategic partnership with Moderna to support genomic research in mRNA-based therapies, underscoring the synergy between genomics and vaccine development.

Data Privacy Concerns on Consumer Genomics: Regulatory scrutiny increased in 2024 over data privacy and misuse concerns in consumer genomics, prompting companies to enhance transparency and security measures.

Key Players

Illumina, Inc. is a global leader in DNA sequencing and array-based technologies. The company is known for its cutting-edge NGS platforms that cater to various applications, including oncology, reproductive health, and microbial genomics. Illumina’s strong R&D investments and product innovations position it at the forefront of genomic solutions worldwide.

Thermo Fisher Scientific Inc. provides a comprehensive portfolio of genomic products, including instruments, reagents, and data analysis tools. Its Ion Torrent sequencing platform and qPCR solutions are widely used across academic, clinical, and industrial settings. Strategic acquisitions and partnerships enhance its global footprint in genomics.

Danaher Corporation operates in the genomics space through subsidiaries like Integrated DNA Technologies and Beckman Coulter. The company focuses on delivering high-quality genomics tools and services, enabling research and clinical applications. Danaher's emphasis on innovation and precision diagnostics is a key driver of its market influence.

F. Hoffmann-La Roche Ltd offers genomics products through its diagnostics division, including sequencing platforms, reagents, and bioinformatics tools. Roche’s commitment to oncology genomics and personalized healthcare solutions has strengthened its role in targeted diagnostics and treatment planning.

Other prominent players in the market include QIAGEN, Agilent Technologies, Inc., Revvity, Charles River Laboratories, Bio-Rad Laboratories, Inc., and Becton, Dickinson and Company.

FAQs

What is the genomics market size in 2024? The genomics market was valued at USD 45.77 billion in 2024.

What is the projected growth rate of the genomics market? The market is expected to grow at a CAGR of 10.20% during 2025-2034.

Which region dominates the genomics market? North America holds the largest market share, driven by strong research infrastructure and healthcare investments.

Which technologies are widely used in genomics? Key technologies include sequencing, PCR, microarrays, and flow cytometry.

Who are the major end users of genomics? End users include pharmaceutical companies, diagnostic labs, hospitals, and academic research institutes. Check Out More Reports Legal Marijuana Market Telemedicine Market Skincare Devices Market Flow Cytometry Market About Us:Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others. Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector. Media Contact: Company Name: Claight Corporation Contact Person: Simran Modi, Digital Marketing Email: sales@expertmarketresearch.com Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790 Address: 30 North Gould Street, Sheridan, WY 82801, USA Website: www.expertmarketresearch.com

[walkingghotst]

Europe Cell Therapy Market Opportunity Assessment, Analysis, Size, Share and Key Segments (2019-2027)

The Europe Cell therapy market is expected to reach US$ 3,610.7 million by 2027 from US$ 2,125.7 million in 2019; it is anticipated to grow at a CAGR of 6.9% during 2019–2027. 

Market Introduction

Cell therapy is a medical procedure involving the introduction of live, whole cells into a patient's body via injection, implantation, or grafting. The fundamental principle of this technology is to restore function by replacing diseased cells with healthy, working ones. Stem cells are central to these advanced therapies because of their unique ability to develop into the specific cell types required to repair damaged or defective tissues. Moreover, cell therapy is integral to the advancement of regenerative medicine. The anticipated growth of the Cell therapy market during the forecast period is likely to be propelled by the increasing incidence of chronic illnesses, the growing utilization of regenerative medicine approaches, and a rising count of approved cell-based therapies.

Download our Sample PDF Report

@ https://www.businessmarketinsights.com/sample/TIPRE00019052

Market Dynamics

Several factors are poised to stimulate the expansion of the Cell therapy market in the years ahead, including the growing prevalence of chronic diseases, the increasing acceptance of regenerative medicine, and the rising number of approvals for cell-based treatments. Conversely, a potential impediment to market growth during the forecast period is the significant expense associated with cell therapy manufacturing, particularly in emerging economies.

The COVID-19 pandemic posed a major challenge throughout the European region. The market for cell therapy instruments experienced some initial contraction at the onset of the crisis due to factors such as supply chain disruptions and decreased demand resulting from widespread lockdowns across European nations. However, subsequent government support and initiatives led to a substantial surge in the demand for cell therapy.

Market Scope

The European Cell therapy market's scope is defined by therapy type, product, technology, application, end user, and country. Considering therapy types, the allogeneic segment held the largest market share in 2019, primarily attributed to the significant number of approved products available for clinical application. Nevertheless, the autologous segment is also expected to exhibit the highest CAGR within the market throughout the forecast period.

Major Sources and Companies Listed

Several major primary and secondary sources associated with the Europe Cell therapy market report are the World Health Organization (WHO), European Centre for Disease Prevention and Control (ECDC), Alliance for Regenerative Medicine, National Institutes of Health, Anthony Nolan Foundation, among others.

EUROPE CELL THERAPY MARKET SEGMENTATION

Europe Cell Therapy Market: By Therapy Type

Allogeneic

Autologous

Europe Cell Therapy Market:  By Product

Consumables

Equipment

Systems and Software

Europe Cell Therapy Market: By Technology

Viral Vector Technology

Genome Editing Technology

Somatic Cell Technology

Cell Immortalization Technology

Cell Plasticity Technology

Three-Dimensional Technology

Europe Cell Therapy Market: By Application

Oncology

Cardiovascular

Orthopedic

Wound Management

Other Applications

Europe Cell Therapy Market: By End User

Research Institutes

Hospitals

Others

Europe Cell Therapy Market: By Country

Germany

France

Italy

UK

Spain

Europe Cell Therapy Market: Company Profiles

Vericel Corporation

MEDIPOST

NuVasive, Inc.

Mesoblast Limited

Smith & Nephew

Bristol-Myers Squibb Company

Cells for Cells

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications

[rainyducktiger]

Artificial Intelligence In Bioinformatics Market Economic Impact and Global Trade Dynamics to 2033

Introduction

The integration of Artificial Intelligence (AI) in bioinformatics is revolutionizing the landscape of life sciences and healthcare. Bioinformatics, which traditionally involves the collection, analysis, and interpretation of biological data, particularly genetic and genomic data, has always demanded complex and large-scale data processing. With the increasing volumes of biological data generated through high-throughput techniques such as next-generation sequencing (NGS), microarrays, and proteomics, AI is becoming indispensable for effective data analysis, interpretation, and predictive modeling.

The Artificial Intelligence in Bioinformatics market is experiencing rapid growth, driven by the expanding application of AI tools in genomics, drug discovery, personalized medicine, and disease prediction. As we move toward 2032, the industry is expected to see significant advancements and investments, influenced by technological innovations, collaborative research, and increasing demand for data-driven healthcare solutions.

Market Overview

Market Size and Growth Rate

As of 2024, the global Artificial Intelligence in Bioinformatics market is valued at approximately USD 1.5 billion, and it is projected to grow at a compound annual growth rate (CAGR) of around 30%, reaching USD 15 billion by 2032. This exponential growth is fueled by the rising need for precision medicine, increased funding in genomics and life sciences, and the surge in AI adoption across various healthcare sectors.

Download a Free Sample Report:-https://tinyurl.com/39xt8fcp

Key Drivers of Market Growth

1. Explosion of Biological Data

The volume of biological and biomedical data is growing at an unprecedented rate. Genomics data alone is expected to surpass several exabytes in the coming years. AI technologies such as machine learning (ML), deep learning (DL), and natural language processing (NLP) are essential in handling, analyzing, and drawing meaningful insights from these massive datasets.

2. Advancements in Genomics and Precision Medicine

AI enables the identification of genetic mutations, variants, and biomarkers that can predict the likelihood of diseases or responses to treatment. This accelerates the development of precision medicine, where treatment is tailored to individual genetic profiles. AI models can integrate multi-omics data (genomics, transcriptomics, proteomics) to provide a holistic understanding of disease mechanisms.

3. Drug Discovery and Development

Traditional drug discovery is time-consuming and costly. AI streamlines this process by predicting molecular behavior, identifying potential drug candidates, and simulating clinical trials. AI can also analyze historical data to avoid redundant research, making drug discovery more efficient.

4. Growing Collaboration Between Tech and Biotech Companies

Tech giants like Google, IBM, Microsoft, and NVIDIA are increasingly investing in AI-driven healthcare and bioinformatics initiatives. Collaborations between tech firms and pharmaceutical or biotechnology companies are leading to innovative platforms for diagnostics, drug design, and genetic analysis.

Application Areas

1. Genomics and Genome Editing

AI plays a critical role in genomic sequence analysis, alignment, annotation, and variant calling. It enhances the capabilities of tools like CRISPR by predicting off-target effects and optimizing gene-editing strategies.

2. Structural Biology and Proteomics

AI models, such as DeepMind’s AlphaFold, have made significant progress in predicting protein structures from amino acid sequences, a task once thought to be extremely complex. This advancement opens new avenues for understanding diseases at the molecular level.

3. Personalized Medicine

By analyzing a patient’s genetic profile and clinical history, AI can suggest personalized treatment plans, dosage recommendations, and even lifestyle changes. This approach not only improves outcomes but also reduces adverse drug reactions.

4. Biomedical Imaging

AI assists in the interpretation of biomedical images, such as MRI or CT scans, by correlating visual patterns with underlying genetic or molecular data. This fusion of imaging and bioinformatics is critical in early disease detection and treatment planning.

5. Clinical Decision Support

AI-driven platforms can support clinicians by providing evidence-based suggestions, diagnostic insights, and predictive analytics. This reduces diagnostic errors and enhances clinical workflow efficiency.

Market Segmentation

By Technology

Machine Learning

Deep Learning

Natural Language Processing

Computer Vision

By Application

Genomics

Transcriptomics

Proteomics

Metabolomics

Drug Discovery

Clinical Diagnostics

By End-User

Pharmaceutical & Biotechnology Companies

Academic & Research Institutes

Hospitals & Clinics

Contract Research Organizations (CROs)

Regional Analysis

North America

North America, particularly the United States, dominates the AI in bioinformatics market due to a well-established healthcare system, advanced research infrastructure, and strong presence of tech and pharmaceutical companies. Government initiatives like the Precision Medicine Initiative and funding from NIH also bolster the growth of AI applications.

Europe

Europe is witnessing significant growth due to investments in healthcare innovation, personalized medicine, and collaborations between universities and biotech firms. The UK, Germany, and France are leading the way in genomics research and AI implementation.

Asia-Pacific

The Asia-Pacific region is poised for rapid expansion, driven by increasing investments in biotechnology, growing prevalence of chronic diseases, and supportive government policies in countries like China, India, Japan, and South Korea.

Rest of the World

Latin America and the Middle East are emerging markets, with growth potential spurred by the modernization of healthcare infrastructure and increased interest in AI technologies.

Challenges and Restraints

1. Data Privacy and Security

Handling sensitive genomic and health data requires robust cybersecurity measures. Compliance with regulations like GDPR, HIPAA, and other data protection laws is a significant challenge for companies.

2. High Cost of Implementation

AI systems require substantial investments in infrastructure, software development, and skilled personnel. This can be a barrier, especially for small- to medium-sized enterprises (SMEs) and developing countries.

3. Lack of Standardization

The absence of standardized data formats, algorithms, and interoperability among systems hampers the integration of AI across platforms and institutions.

4. Skill Gap

There is a shortage of professionals who possess both domain knowledge in life sciences and expertise in AI technologies. Bridging this gap is crucial for market growth.

Future Outlook

The future of Artificial Intelligence in Bioinformatics is exceptionally promising. Over the next decade, we can expect:

Greater integration of AI with blockchain for secure data sharing and transparency in clinical trials.

Advances in explainable AI (XAI) to improve trust and understanding among clinicians and researchers.

Development of AI-powered biosensors and wearables for continuous health monitoring and real-time data analysis.

Decentralized research models, enabled by federated learning, where data remains localized while AI models are trained collaboratively across institutions.

Global standardization efforts, led by regulatory bodies and consortiums, to ensure interoperability and ethical AI deployment.

Key Players in the Market

IBM Corporation

Google LLC (DeepMind)

NVIDIA Corporation

Microsoft Corporation

Illumina, Inc.

Thermo Fisher Scientific Inc.

BioXcel Therapeutics

BenevolentAI

Insilico Medicine

Sophia Genetics

These companies are investing in R&D, forming strategic partnerships, and developing proprietary AI platforms to stay competitive in this rapidly evolving market.

Conclusion

Artificial Intelligence is poised to transform the bioinformatics landscape, making it more intelligent, efficient, and predictive. From understanding the human genome to discovering new drugs and enabling personalized medicine, the synergy between AI and bioinformatics holds the key to future breakthroughs in healthcare and life sciences. While challenges remain, the momentum is undeniable, and by 2032, AI will be an integral part of every major bioinformatics process. Stakeholders who invest early in this space—whether through technology development, partnerships, or talent acquisition—will be best positioned to lead in the next era of medical innovation.

Read Full Report:-https://www.uniprismmarketresearch.com/verticals/healthcare/artificial-intelligence-in-bioinformatics.html

[global-research-report]

Emerging Trends in the U.S. Gene Therapy Market: Regulatory Landscape & Future Prospects

The U.S. gene therapy market size is anticipated to reach USD 10.40 billion by 2030, expanding at a CAGR of 19.21% during the forecast period, according to a new report by Grand View Research, Inc. The market growth can be attributed to various factors such as the expanding area of advanced therapies along with gene delivery technologies and increased competition among key players focused on the commercialization of their therapies.

Similar to many other industries, the COVID-19 pandemic has had an impact on the U.S. market for gene therapy. While the market is expected to grow significantly in the coming years, the pandemic has caused delays in clinical trials and disruptions in the supply chain. The pandemic also highlighted the importance of gene therapy in treating and preventing diseases, which could lead to increased funding and investment in the field. Overall, while the pandemic has caused some challenges for the U.S. gene therapy industry, there is still significant potential for growth and advancement in the coming years.

The gene therapy pipeline in the U.S. is currently quite robust, with several promising therapies in various stages of development. Many of these therapies focus on rare genetic diseases, such as spinal muscular atrophy, choroideremia, Duchenne muscular dystrophy, and hemophilia. In addition, gene editing technologies like CRISPR-Cas9 are being used to develop therapies that can target specific genetic mutations with greater precision. For instance, in December  2023, Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics jointly made the announcement of CASGEVY (exagamglogene autotemcel [exa-cel]), a genome modified cell therapy using CRISPR/Cas9 technology, has been approved by the U.S. FDA for treating sickle cell disease in patients aged 12 and above who have recurrent vaso-occlusive crises (VOCs).

However, drug companies have attached very high prices to these narrowly targeted treatments, resulting in one being pulled from the market in Europe and another struggling to attract patients. For instance, in November 2023, Sarepta Therapeutics revealed the price of the drug per infusion of the Elevidys, gene therapy for Duchenne muscular dystrophy (DMD), which is approximately USD 3.2 million.

U.S. Gene Therapy Market Report Highlights

Large B-cell lymphoma dominated the indication segment with the largest revenue share of 36.04% in 2023. This is attributed to the high prevalence of this type of cancer in the country. Additionally, gene therapy has shown promising results in treating this disease, leading to increased adoption by healthcare providers and patients.

The intravenous route of administration held the larger market share in 2023 and is expected to grow at a higher CAGR during the forecast period. This route of administration involves the use of viruses, such as adenovirus, retrovirus, or lentivirus, to deliver the desired gene into the patient's cells.

Based on vector type, the lentivirus segment dominated with the largest revenue share in 2023. On the other hand, AAV is anticipated to grow at the highest CAGR from 2024 to 2030, owing to the rising demand and their usage in clinical trialsdue to the higher accuracy level in delivering the gene to the region of interest.

Curious about the U.S. Gene Therapy Market? Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

U.S. Gene Therapy Market Segmentation

Grand View Research has segmented the U.S. gene therapy market based on indication, route of administration, and vector type:

U.S. Gene Therapy Indication Outlook (Revenue, USD Million, 2018 - 2030)

Large B-cell Lymphoma

Multiple Myeloma

Spinal Muscular Atrophy (SMA)

Acute Lymphoblastic Leukemia (ALL)

Melanoma (lesions)

Inherited Retinal Disease

Beta-thalassemia Major/SCD

Others

U.S. Gene Therapy Route Of Administration Outlook (Revenue, USD Million, 2018 - 2030)

Intravenous

Others

U.S. Gene Therapy Vector Type Outlook (Revenue, USD Million, 2018 - 2030)

Lentivirus

RetroVirus & Gamma RetroVirus

AAV

Modified Herpes Simplex Virus

Adenovirus

Others

Key Players in the U.S. Gene Therapy Market

Amgen Inc.

Novartis AG

Hoffmann-La Roche

Gilead Sciences, Inc.

bluebird bio, Inc.

Bristol-Myers Squibb Company

Legend Biotech.

uniQure N.V.

Merck & Co.

Sarepta Therapeutics, Inc.

Krystal Biotech, Inc.

CRISPR Therapeutics.

Order a free sample PDF of the U.S. Gene Therapy Market Intelligence Study, published by Grand View Research.

[towards003]

Unlocking the Future: How Genetic Material is Revolutionizing Medicine, Agriculture, and Beyond

The genetic material market is on the cusp of a transformative decade, fueled by groundbreaking advancements in gene therapies, personalized medicine, and biopharmaceutical research. With the rapid expansion of genomic data, CRISPR-based gene editing, and synthetic biology applications, this market is set to reshape healthcare, agriculture, and biotechnology. As governments boost funding and regulatory frameworks evolve to support innovation, genetic material is emerging as a cornerstone of the future bioeconomy.

North America Leads, Asia Pacific Rises North America dominated the genetic material market in 2024, driven by strong investments in genomics and biotechnology. Meanwhile, Asia Pacific is positioned to grow at the fastest rate during the forecast period, with increasing research collaborations, government support, and technological advancements fueling the expansion.

DNA and RNA: The Building Blocks of Innovation DNA continued to hold the largest market share in 2024, widely used in biotechnology, pharmaceuticals, and genetic engineering. However, RNA is emerging as the fastest-growing segment, with promising applications in targeting previously "undruggable" proteins, transcripts, and genes. Advances in RNA-based therapies are revolutionizing drug development, offering novel approaches for treating a range of diseases.

Genomics and Drug Discovery Drive Growth Genomics remained the dominant application in 2024, providing vital insights into human genes and their functions. This knowledge is unlocking new drug development pathways and paving the way for personalized medicine. Drug discovery is another rapidly growing sector, with human genetic data playing a crucial role in improving clinical trial success rates and identifying new therapeutic targets.

AI Reshaping Genetic Research Artificial intelligence (AI) is revolutionizing genomics research by enhancing the ability to analyze vast amounts of genetic data. AI-driven algorithms can detect genetic variations linked to diseases and predict how genes and proteins function, accelerating drug discovery and improving precision medicine. As AI continues to integrate with genetic research, it promises to unlock deeper insights into human health and disease mechanisms.

Key Market Drivers and Challenges

Gene and Cell Therapies Transform Healthcare Innovations in cell and gene therapies (CGTs) are redefining treatment standards, offering potential cures for chronic illnesses. Companies are developing allogeneic cell therapies that can be mass-produced, making advanced treatments more accessible. The rise of CGTs signals a healthcare revolution, with unprecedented therapeutic outcomes on the horizon.

Complex Data Interpretation Poses a Challenge While genetic research is advancing rapidly, interpreting complex genetic data remains a significant hurdle. Expertise in bioinformatics, statistics, and molecular biology is essential to extract meaningful insights. The shortage of skilled professionals in these areas limits the pace of genetic discoveries and their application in clinical settings.

Research Collaborations and Technology Accelerate Growth Partnerships between research institutions, biotech firms, and pharmaceutical companies are driving innovation in genetic material analysis. Advances in sequencing technology, gene editing tools, and data analytics are enhancing the accuracy and scalability of genetic research, opening new doors for disease prevention and treatment.

Source: https://www.towardshealthcare.com/insights/genetic-material-market-sizing

[industrynewsupdates]

Challenges and Opportunities in the Latin America Molecular Methods Market for Food Safety Testing

The Latin America molecular methods market for food safety testing size is expected to reach USD 191.8 million by 2030, registering a CAGR of 3.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to improvement in safety regulations of edibles, the introduction of automation in food testing protocols, the growing burden of food-borne illness, and a rise in demand for ultra-processed, packaged, and organic food products.

The government authorities are continuously strengthening their surveillance and detection methods to monitor the supply chain of edibles. This minimizes the contamination risks and increases the demand for food safety testing solutions, which, in turn, drives the market. Several agencies, laws and regulations; such as Pan American Health Organization (PAHO), Food and Agricultural Import Regulations and Standards, Regulation and Control of Food, and others; are present to regulate the food safety testing industry as well as govern the interstate and international food trade.

Many countries in the Latin America region are also undertaking efforts to align their regulatory framework with the requirement of the World Trade Organization (WTO), Sanitary and Phytosanitary (SPS) measures, and Technical Barriers to Trade agreements. In addition, these nations are actively seeking to facilitate mechanisms, such as the use of equivalence agreements for sanitary registration.

Moreover, universities and institutes, such as the National University of San Marcos, provide courses and training on food microbiology, hygiene, and safety of edibles. These factors are anticipated to build the capacity pertaining to safety of edibles and risk analysis and consequently strengthen the laboratory networks in Latin America.

Request Free Sample PDF of Latin America Molecular Methods Market For Food Safety Testing Size, Share & Trends Analysis Report

Latin America Molecular Methods Market For Food Safety Testing Report Highlights

• Based on technology, the Polymerase Chain Reaction (PCR) segment accounted for the largest market revenue share in 2024. Initiatives to enhance food safety and regional cooperation drive the adoption of PCR technology for efficient and accurate food safety testing across the region.

• Based on product, The reagents and consumables segment dominated the market and accounted for a share of 49.4% in 2024. The need for advanced diagnostic solutions to detect and prevent foodborne diseases, including those transmitted by vectors, drives demand for molecular testing tools in the region

• The instrument segment is expected to grow at the fastest CAGR of 4.2% over the forecast period. The increasing demand for rapid, accurate, and reliable testing solutions is driven by the need to ensure food safety and meet strict regulatory standards.

• The Brazil molecular methods market for food safety testing dominated the Latin America market with a share of 38.0% in 2024 due to the growing need for efficient and cost-effective regulatory frameworks to ensure biosafety in the agriculture sector, driven by the adoption of innovative genome-editing technologies.

• Key players have expanded their presence in the Latin American region to enhance their presence. For instance, in January 2020, Eurofins Scientific established its third field station in Brazil in Cambé, Paraná. The center has a team of agronomists that are engaged in conducting a wide variety of trials, such as efficacy, ecotoxicology, residue, and GMO studies to analyze crops including wheat, soybean, potato, corn, vegetables, coffee, and tomato

Latin America Molecular Methods Market For Food Safety Testing Segmentation

Grand View Research has segmented the Latin America molecular methods market for food safety testing on the basis of on product, technology, and region

Latin America Molecular Methods Market For Food Safety Testing  Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instrument

• Reagents & Consumables

• Services

Latin America Molecular Methods Market For Food Safety Testing  Technology Outlook (Revenue, USD Million, 2018 - 2030)

• PCR

• Immunoassay

• Biosensors

• Microarray

• Others

Latin America Molecular Methods Market For Food Safety Testing  Regional Outlook (Revenue, USD Million, 2018 - 2030)

• Latin America

o Brazil

o Argentina

o Chile

o Colombia

o Peru

o Ecuador

o Dominican Republic

o Guatemala

o Cuba

o Panama

o Venezuela

o Costa Rica

o Uruguay

List of Key Players in the Latin America Molecular Methods Market For Food Safety Testing

• QIAGEN

• Eurofins Scientific

• 3M

• Bio-Rad Laboratories, Inc.

• Société Générale de Surveillance SA. (SGS)

• BIOMÉRIEUX

• NEOGEN Corporation

• Hygiena LLC

• Seegene Inc.

• Thermo Fisher Scientific Inc.

Order a free sample PDF of the Latin America Molecular Methods Market for Food Safety Testing Intelligence Study, published by Grand View Research.

[healthcaremmr]

The Genome Editing Market size was valued at USD 7.23 Bn in 2023 and market revenue is growing at a CAGR of 15.8 % from 2023 to 2030, reaching nearly USD 20.19 Bn by 2030.

[fortunatelypsychiceagle]

Europe Synthetic Biology Market Size, Share, Comprehensive Analysis, Opportunity Assessment by 2030

The Europe Synthetic Biology Market is a rapidly evolving sector with significant growth potential, driven by advancements in biotechnology, increasing demand for sustainable solutions, and diverse applications across industries. Below is a detailed breakdown of the market segmentation, key trends, and competitive landscape: 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 - https://www.businessmarketinsights.com/sample/BMIRE00025389

Europe Synthetic Biology Market Segmentation

By Product:

Enzymes: Widely used in industrial and medical applications due to their catalytic properties.

Chassis Organisms: Engineered microorganisms used as platforms for synthetic biology applications.

Oligonucleotides: Dominated the market in 2020, driven by their use in diagnostics, therapeutics, and research.

Xeno-Nucleic Acids (XNAs): Emerging segment with potential applications in biotechnology and medicine.

By Technology:

Measurement & Modeling: Essential for understanding and predicting biological systems.

Cloning & Sequencing: Foundational technologies for genetic engineering.

Genome Engineering: Expected to grow at the fastest CAGR, driven by CRISPR and other gene-editing tools.

Gene Synthesis: Dominated the market in 2020, enabling the creation of custom DNA sequences.

Nanotechnology: Increasingly integrated with synthetic biology for advanced applications.

Others: Includes bioinformatics and automation technologies.

By Application:

Medical Applications: Dominated the market in 2020, with growth driven by gene therapies, personalized medicine, and vaccine development.

Industrial Applications: Includes bio-manufacturing of chemicals, materials, and biofuels.

Food and Agriculture: Focused on engineered crops, alternative proteins, and sustainable farming solutions.

Environmental Applications: Includes bioremediation and carbon capture technologies.

Others: Includes research and educational applications.

By Country:

UK: A leading hub for synthetic biology research and innovation.

Germany: Strong industrial base and government support for biotechnology.

France: Growing investments in synthetic biology for healthcare and agriculture.

Italy: Emerging market with increasing R&D activities.

Spain: Focused on environmental and agricultural applications.

Rest of Europe: Includes countries like Switzerland, the Netherlands, and Nordic nations, which are also significant contributors.

Key Trends and Insights

Regulatory Environment:

Europe has stringent regulations for genetically modified organisms (GMOs) and synthetic biology products, which can impact market entry and innovation.

The European Medicines Agency (EMA) and European Food Safety Authority (EFSA) play critical roles in approving synthetic biology-based products.

Consumer Preferences:

Increasing demand for sustainable and eco-friendly products is driving innovation in industrial and environmental applications.

In medical applications, there is a growing preference for personalized and precision medicine.

Economic Conditions:

Western Europe (UK, Germany, France) has well-established biotechnology sectors, while Southern and Eastern Europe are emerging markets with growth potential.

Public and private funding for synthetic biology research is increasing across the region.

Technological Advancements:

CRISPR and other genome-editing tools are revolutionizing the field.

Automation and AI are enhancing the efficiency of synthetic biology workflows.

Underserved Areas:

Eastern Europe and parts of Southern Europe present opportunities for market expansion due to lower competition and growing interest in biotechnology.

Competitive Landscape

The Europe synthetic biology market is highly competitive, with key players including:

Agilent Technologies, Inc.

Amyris

Codexis

Genscript Biotech Corporation

Integrated DNA Technologies

Merck KGaA

New England Biolabs

Novozymes A/S

Thermo Fisher Scientific

Twist Bioscience

These companies are focusing on strategic initiatives such as partnerships, acquisitions, and R&D investments to strengthen their market position. For example:

Twist Bioscience is a leader in gene synthesis and DNA data storage.

Novozymes focuses on industrial enzymes and sustainable solutions.

Merck KGaA is expanding its portfolio in genome engineering and gene synthesis.

Growth Drivers

Increasing Demand for Personalized Medicine:

Synthetic biology enables the development of tailored therapies, driving growth in the medical applications segment.

Sustainability Initiatives:

Synthetic biology offers solutions for bio-based materials, renewable energy, and waste reduction, aligning with Europe’s Green Deal objectives.

Technological Innovations:

Advances in gene editing, automation, and AI are accelerating research and commercialization.

Government Support:

Funding programs and initiatives, such as Horizon Europe, are boosting synthetic biology research and innovation.

Challenges

Regulatory Hurdles:

Strict GMO regulations can slow down the approval and commercialization of synthetic biology products.

Public Perception:

Concerns about the ethical and environmental implications of synthetic biology may hinder market growth.

High R&D Costs:

Developing synthetic biology products requires significant investment, which can be a barrier for smaller companies.

Conclusion

The Europe synthetic biology market is poised for significant growth, driven by technological advancements, increasing demand for sustainable solutions, and diverse applications across industries. Companies that can navigate regulatory challenges, adapt to local market conditions, and leverage emerging technologies will be well-positioned to capitalize on the opportunities in this dynamic market.

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Défense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications

Author’s Bio: Snehal Senior Market Research Expert at Business Market InsightsBrowse more Reports Europe Frozen Fruits Size -https://businessmarketins02.blogspot.com/2025/02/europe-frozen-fruits-size-share.html   Europe Power over Ethernet Market - https://businessmarketins02.blogspot.com/2025/02/europe-power-over-ethernet-market-size.html US Sleepwear Market - https://businessmarketins02.blogspot.com/2025/02/us-sleepwear-market-size-share-trends.html